Anzeige
Meldung des Tages: Noch unter 2x Umsatz bewertet – aber wie lange noch?

Insmed Aktie News

Aktie
WKN:  A1JJA3 ISIN:  US4576693075 US-Symbol:  INSM Branche:  Biotechnologie Land:  USA
160,98 $
+9,87 $
+6,53%
136,75 € 22:00:00 Uhr
Depot/Watchlist
Marktkapitalisierung *
27,47 Mrd. €
Streubesitz
-
KGV
-28,49
Nachhaltigkeits-Score
45 %
Index-Zuordnung
Nasdaq 100
Weiter aufwärts? Long handeln - Jetzt mit Hebel 7,43: MM3E2V
Werbung

Insmed News

21:37 Uhr - ARIVA.DE Redaktion
Nasdaq 100 im Minus: das Aktienbarometer verliert 31 Punkte (24.733 Pkt.)
Am Aktienmarkt ist die Stimmung für den Nasdaq 100 derzeit etwas getrübt. Das Kursbarometer verliert 31 Punkte.
07:00 Uhr - PR Newswire
Insmed Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Business Update
Insmed Reports Fourth-​Quarter and Full-Year 2025 Financial Results and Provides Business Update PR Newswire
13.02.26 - PR Newswire
Insmed To Present at March 2026 Investor Conferences
Insmed To Present at March 2026 Investor Conferences PR Newswire
05.02.26 - PR Newswire
Insmed to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026
Insmed to Host Fourth-​Quarter and Full-Year 2025 Financial Results Conference Call on Thursday, February 19, 2026 PR Newswire
28.01.26 - PR Newswire
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress PR Newswire
22.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM PR Newswire
15.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM PR Newswire
09.01.26 - PR Newswire
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference
Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference PR Newswire
08.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM PR Newswire
02.01.26 - PR Newswire
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference
Insmed To Present at the 44th Annual J.P. Morgan Healthcare Conference PR Newswire
01.01.26 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Insmed Incorporated - INSM PR Newswire
17.12.25 - PR Newswire
Insmed Provides Clinical and Business Update
Insmed Provides Clinical and Business Update PR Newswire
04.12.25 - PR Newswire
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) PR Newswire
18.11.25 - PR Newswire
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
European Commission Approves BRINSUPRI® (brensocatib) as the First and Only Treatment To Date Approved for Non-​Cystic Fibrosis Bronchiectasis in the European Union PR ...
18.11.25 - PR Newswire
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-Cystic Fibrosis Bronchiectasis in the European Union
European Commission Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment Approved for Non-​Cystic Fibrosis Bronchiectasis in the European Union PR Newswire
17.11.25 - wallstreetONLINE Redaktion
Nach Verkauf von Microsoft: Milliardär Stanley Druckenmiller investiert 95.967.000 Dollar in E-Commerce & KI
Der Milliardär Stanley Druckenmiller hat gerade seine Beteiligung an Microsoft abgestoßen und gleichzeitig Millionen Dollar in eine Wette auf E-​Commerce, KI und Robotik ...
13.11.25 - PR Newswire
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good
Insmed Strengthens Communities Worldwide During Fourth Annual Global Day of Good PR Newswire
05.11.25 - PR Newswire
Insmed To Present at November and December 2025 Investor Conferences
Insmed To Present at November and December 2025 Investor Conferences PR Newswire
30.10.25 - PR Newswire
Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update
Insmed Reports Third-​Quarter 2025 Financial Results and Provides Business Update PR Newswire
23.10.25 - PR Newswire
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List PR Newswire

Newssuche

Videos

newspaper
18.02.26 +11,65%
Technical Trading: Chance mit 82 Prozent Treffern
Rohöl Long Typ: Turbo Open End WKN: VH65XQ Hebel:6 Laufzeit: OpenEnd Einstieg: Market ... Mehr »